Cassava Sciences (SAVA) just unveiled an update.
Remi Barbier, President and CEO of Cassava Sciences, resigned effective September 13, 2024, and will receive severance and benefits per his employment agreement, while Richard J. Barry steps in as Executive Chairman. In parallel, Dr. Lindsay Burns, SVP of Neuroscience, has transitioned to a consulting role with a severance package and will continue to support Cassava’s research efforts. These strategic changes, aiming to leverage experience and ensure continuity, were detailed in Cassava’s recent press release and regulatory filings.
For an in-depth examination of SAVA stock, go to TipRanks’ Stock Analysis page.
